Fagron NV 2025 AR2
The report highlights Fagron's strong performance in 2025, with revenue increasing by 9.2% to 952.2 million euros and net result rising by 13.0% to 91.5 million euros. The company successfully executed its 'Future Forward: Personalizing Medicine' sustainability strategy, achieving a 41% reduction in Scope 1 and 2 greenhouse gas emissions compared to the 2021 baseline. Fagron also expanded its global footprint through twelve acquisitions across EMEA, Latin America, and North America-Pacific, including EuroOTC, Guinama, and CareFirst. Additionally, the company improved product availability to over 90% and achieved an employee engagement score of 87%.
Company: Fagron NV
Sector: Health Care
Country: Belgium
Year: 2025
Type: AR2
Pages: 296
Fagron NV
Annual Report
The report highlights Fagron's strong performance in 2025, with revenue increasing by 9.2% to 952.2 million euros and net result rising by 13.0% to 91.5 million euros. The company successfully executed its 'Future Forward: Personalizing Medicine' sustainability strategy, achieving a 41% reduction in Scope 1 and 2 greenhouse gas emissions compared to the 2021 baseline. Fagron also expanded its global footprint through twelve acquisitions across EMEA, Latin America, and North America-Pacific, including EuroOTC, Guinama, and CareFirst. Additionally, the company improved product availability to over 90% and achieved an employee engagement score of 87%.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jan 1, 2025 - Dec 31, 2025
Fiscal Year
2025
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Net Zero Target
Employees